EANM practice guideline for PET/CT imaging in medullary thyroid carcinoma

Giovanella, Luca; Treglia, Giorgio; Iakovou, Ioannis; Mihaïlovic, Jasna; Verburg, Frederik A.; Luster, Markus

doi:10.1007/s00259-019-04458-6

Cited by 85 publications

(66 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Physical examinations and neck US should also be performed every 6-12 months. When bCtn levels exceed 150 pg/mL, imaging procedures, including neck US, chest CT, contrast-enhanced CT/MRI of the liver, bone scintigraphy and MRI of the pelvis and axial skeleton, and/or PET/CT should be performed to detect persistent, residual, or metastatic MTC (2,81,82). For patients with biochemical recurrence with negative imaging, a watchful waiting approach could be applied.…”

Section: Personalized Precision Treatment Of Men2mentioning

confidence: 99%

5P Strategies for Management of Multiple Endocrine Neoplasia Type 2: A Paradigm of Precision Medicine

Ding

et al. 2020

Front. Endocrinol.

View full text Add to dashboard Cite

Multiple endocrine neoplasia type 2 (MEN2) is a neuroendocrine cancer syndrome characterized by medullary thyroid carcinoma, in combination or not with pheochromocytoma, hyperparathyroidism, and extra-endocrine features. MEN2 syndrome includes two clinically distinct forms subtyped as MEN2A and MEN2B. Nearly all MEN2 cases are caused by germline mutations of the RET proto-oncogene. In this review, we propose "5P" strategies for management of MEN2: prevention, prediction, personalization, psychological support, and participation, which could effectively improve clinical outcomes of patients. Based on RET mutations, MEN2 could be prevented through prenatal diagnosis or preimplantation genetic testing. Identification of pathogenic mutations in RET can enable early diagnosis of MEN2. Combining RET mutation testing with measurement of serum calcitonin, plasma or urinary metanephrine/normetanephrine, and serum parathyroid hormone levels could allow risk stratification and accurately prediction of MEN2 progression, thus facilitating implementation of personalized precision treatments to increase disease-free survival and overall survival. Furthermore, increased awareness of MEN2 is needed, which requires participation of physicians, patients, family members, and related organizations. Psychological support is also important for patients with MEN2 to promote comprehensive management of MEN2 symptoms. The "5P" strategies for management of MEN2 represent a typical clinical example of precision medicine. These strategies could effectively improve the health of MEN2 patient, and avoid adverse outcomes, including death and major morbidity, from MEN2.

show abstract

Section: Personalized Precision Treatment Of Men2mentioning

confidence: 99%

5P Strategies for Management of Multiple Endocrine Neoplasia Type 2: A Paradigm of Precision Medicine

Ding

et al. 2020

Front. Endocrinol.

View full text Add to dashboard Cite

show abstract

“…4,[25][26] Furthermore, 18 F-FDG PET/ CT is able to accurately identify MTC patients with poor prognosis and life expectancy, and to evaluate response to targeted therapies in patients with advanced metastatic disease. 27 Our investigation showed that progression-free survival in FDG TP patients showed median survival of 15 months in the patients with recurrences and metastases, while median progression-free survival in disease free patients at the moment of investigation was 30 months. This is in accordance with the results of other authors.…”

Section: Discussionmentioning

confidence: 59%

“…CEA levels disproportionately high compared with calcitonin levels). 27,39 According to Kushchayev et al, functional imaging, primarily PET/CT with 18 F-FDOPA and 18 F-FDG, plays a crucial role in the evaluation and management of MTC and has proven to be an efficient tool for the detection of metastases in patients with elevated calcitonin levels. 40 Furthermore, 68 Ga-SSA PET/CT could be considered in the cases with inconclusive anatomic imaging, 18 F-FDOPA and 18 F-FDG PET/ CT results as well to assess the feasibility of peptide receptor radionuclide therapy.…”

mentioning

confidence: 99%

Clinical relevance of ¹⁸F-FDG PET/CT in the postoperative follow-up of patients with history of medullary thyroid cancer

Saponjski

Macut

Šaranović

et al. 2020

Radiology and Oncology

View full text Add to dashboard Cite

BackgroundThe aim of the study was evaluation of 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography with computed tomography (PET/CT) in the detection of active disease in the patients with suspected recurrence of the medullary thyroid carcinoma (MTC).Patients and methods18F-FDG PET/CT investigation was performed in 67 patients, investigated from 2010 to 2019. _ Follow up was performed from 6 to 116 months after surgery (median 16.5 months, x± SD = 29±28.9 months). Twenty five of 67 patients underwent 99mTc-dimercaptosuccinic acid (99mTc-DMSA) scintigraphy, 11 underwent somatostatin receptor scintigraphy (SRS) with 99mTc-HYNIC TOC while 11 123I-metaiodobenzylguanidine (MIBG) scintigraphy.ResultsFrom 67 patients, 35 (52.2%) had true positive 18F-FDG PET/CT findings (TP). Average maximal standardized uptake value (SUVmax) for all TP lesions was 5.01+3.6. In 25 (37.3%) patients findings were true negative (TN). Four (6%) patients had false positive (FP) findings while three (4.5%) were false negative (FN). Thus, sensitivity of the 18F-FDG PET/ CT was 92.11%, specificity 86.21%, positive predictive value 89.74%, negative predictive value 89.29% and accuracy 89.55%. In 27 patients (40%) 18F-FDG PET/CT finding influenced further management of the patient.Conclusions18F-FDG PET/CT has high accuracy in the detection of metastases/recurrences of MTC in patients after thyroidectomy as well as in evaluation and the appropriate choice of the therapy.

show abstract

“…A clinical trial revealed that NKO-035 has high affinity for LAT1 (Japanese Registry of Clinical Trials, jRCTs051190057). Of these, 18 F-FDOPA and 11 C-MET have been assessed among TC patients [68,69]. 18 F-FDOPA PET/CT is a suitable modality for detecting metastatic, persistent, and residual MTC; however, 18 F-FDG PET/CT may be considered for aggressive MTC in cases displaying signs of dedifferentiation or rapidly rising CEA levels [68,69].…”

Section: Diagnosis Via Positron Emission Tomographymentioning

confidence: 99%

“…Of these, 18 F-FDOPA and 11 C-MET have been assessed among TC patients [68,69]. 18 F-FDOPA PET/CT is a suitable modality for detecting metastatic, persistent, and residual MTC; however, 18 F-FDG PET/CT may be considered for aggressive MTC in cases displaying signs of dedifferentiation or rapidly rising CEA levels [68,69]. Thus far, 11 C-MET PET has not been proven superior to 18 F-FDG PET in detecting recurrent differentiated TC [70].…”

Section: Diagnosis Via Positron Emission Tomographymentioning

confidence: 99%

Amino Acid Transporters as Potential Therapeutic Targets in Thyroid Cancer

Enomoto

Hotomi

2020

Endocrinol Metab

View full text Add to dashboard Cite

Thyroid cancer cells have a high amino acid demand for proliferation, invasion, and metastasis. Amino acids are taken up by thyroid cancer cells, both thyroid follicular cell and thyroid parafollicular cells (commonly called "C-cells"), via amino acid transporters. Amino acid transporters up-regulate in many cancers, and their expression level associate with clinical aggressiveness and prognosis. This is the review to discuss the therapeutic potential of amino acid transporters and as molecular targets in thyroid cancer.

show abstract

EANM practice guideline for PET/CT imaging in medullary thyroid carcinoma

Cited by 85 publications

References 66 publications

5P Strategies for Management of Multiple Endocrine Neoplasia Type 2: A Paradigm of Precision Medicine

5P Strategies for Management of Multiple Endocrine Neoplasia Type 2: A Paradigm of Precision Medicine

Clinical relevance of ¹⁸F-FDG PET/CT in the postoperative follow-up of patients with history of medullary thyroid cancer

Amino Acid Transporters as Potential Therapeutic Targets in Thyroid Cancer

Contact Info

Product

Resources

About

EANM practice guideline for PET/CT imaging in medullary thyroid carcinoma

Cited by 85 publications

References 66 publications

5P Strategies for Management of Multiple Endocrine Neoplasia Type 2: A Paradigm of Precision Medicine

5P Strategies for Management of Multiple Endocrine Neoplasia Type 2: A Paradigm of Precision Medicine

Clinical relevance of 18F-FDG PET/CT in the postoperative follow-up of patients with history of medullary thyroid cancer

Amino Acid Transporters as Potential Therapeutic Targets in Thyroid Cancer

Contact Info

Product

Resources

About

Clinical relevance of ¹⁸F-FDG PET/CT in the postoperative follow-up of patients with history of medullary thyroid cancer